npj Vaccines (Nov 2023)
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
- Rajesh M. Valanparambil,
- Lilin Lai,
- Margaret A. Johns,
- Meredith Davis-Gardner,
- Susanne L. Linderman,
- Tarrant Oliver McPherson,
- Andres Chang,
- Akil Akhtar,
- Estefany L. Bocangel Gamarra,
- Hayley Matia,
- Ashley A. McCook-Veal,
- Jeffrey Switchenko,
- Tahseen H. Nasti,
- Felicia Green,
- Manpreet Saini,
- Andreas Wieland,
- Benjamin A. Pinsky,
- Daniel Solis,
- Madhav V. Dhodapkar,
- Jennifer Carlisle,
- Suresh Ramalingam,
- Rafi Ahmed,
- Mehul S. Suthar
Affiliations
- Rajesh M. Valanparambil
- Emory Vaccine Center, Emory University School of Medicine
- Lilin Lai
- Emory Vaccine Center, Emory University School of Medicine
- Margaret A. Johns
- Winship Cancer Institute of Emory University
- Meredith Davis-Gardner
- Emory Vaccine Center, Emory University School of Medicine
- Susanne L. Linderman
- Emory Vaccine Center, Emory University School of Medicine
- Tarrant Oliver McPherson
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University
- Andres Chang
- Emory Vaccine Center, Emory University School of Medicine
- Akil Akhtar
- Emory Vaccine Center, Emory University School of Medicine
- Estefany L. Bocangel Gamarra
- Emory Vaccine Center, Emory University School of Medicine
- Hayley Matia
- Winship Cancer Institute of Emory University
- Ashley A. McCook-Veal
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University
- Jeffrey Switchenko
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University
- Tahseen H. Nasti
- Emory Vaccine Center, Emory University School of Medicine
- Felicia Green
- Winship Cancer Institute of Emory University
- Manpreet Saini
- Emory Vaccine Center, Emory University School of Medicine
- Andreas Wieland
- Emory Vaccine Center, Emory University School of Medicine
- Benjamin A. Pinsky
- Department of Pathology, Stanford University School of Medicine
- Daniel Solis
- Department of Pathology, Stanford University School of Medicine
- Madhav V. Dhodapkar
- Winship Cancer Institute of Emory University
- Jennifer Carlisle
- Winship Cancer Institute of Emory University
- Suresh Ramalingam
- Winship Cancer Institute of Emory University
- Rafi Ahmed
- Emory Vaccine Center, Emory University School of Medicine
- Mehul S. Suthar
- Emory Vaccine Center, Emory University School of Medicine
- DOI
- https://doi.org/10.1038/s41541-023-00779-8
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 4
Abstract
Abstract This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in most of the healthy participants, patients with NSCLC had significantly reduced nAb titers after 4–6 months of vaccination. Our data highlight the importance of COVID-19 bivalent booster vaccination as the standard of care for patients with NSCLC given the evolution of new variants of concern.
